Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes
Dauerhafte Behandlung mit GLP-1-Rezeptoragonisten verbessert die glykämische Kontrolle und senkt die Gesamtmortalität im Vergleich zu DPP-4-Inhibitoren: eine Real-World-Target-Trial-Emulation bei Typ-2-Diabetes
Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 3974-3984
DOI: 10.1111/dom.70581 ↗Auf einen Blick
Bei Menschen mit Typ-2-Diabetes war eine dauerhafte GLP-1-RA-Therapie mit besserer HbA1c-Verbesserung und geringerer Gesamtmortalität verbunden als DPP-4-Inhibitoren.
Fragestellung
Wie wirksam ist eine dauerhafte GLP-1-RA-Anwendung im Vergleich zu DPP-4-Inhibitoren in der Routineversorgung hinsichtlich HbA1c-Verbesserung und Mortalität?
Methode
Target-Trial-Emulation mit dänischen Registerdaten (2012–2022); Vergleich von GLP-1-RAs mit DPP-4is; Analyse mit Longitudinal Targeted Minimum Loss-based Estimation.
Ergebnisse
16 619 GLP-1-RA- und 34 196 DPP-4i-Initierende. Nach 1 Jahr: HbA1c-Verbesserung 82,7 % (95 %-KI 82,0 %–83,4 %) vs. 67,1 % (95 %-KI 66,5 %–67,6 %); absolute Differenz 15,7 % (95 %-KI 14,8 %–16,5 %).
Einschränkungen
Limitations of this nationwide study and the available data.
Schlussfolgerung der Autor:innen
Nach Ansicht der Autor:innen zeigte die dauerhafte GLP-1-RA-Therapie eine überlegene glykämische Kontrolle und war mit einem moderaten Mortalitätsvorteil gegenüber DPP-4i verbunden.
Kernaussagen
- HbA1c-Verbesserung nach 1 Jahr häufiger unter GLP-1-RA
- Absolute Differenz 15,7 % (95 %-KI 14,8 %–16,5 %)
- Gesamtmortalität unter GLP-1-RA geringer
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 25.02.2026. Verfasst von Kathrine Kold Sørensen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen University Hospital, Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Glycemic Control. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union, European Commission.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain.
Aim
To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4 inhibitors (DPP‐4is) as an active comparator.
Methods
Using Danish nationwide registries (2012–2022), we emulated a target trial assessing the glycemic effectiveness of GLP‐1 RAs. The primary outcome was the probability of improvement in defined HbA1c categories within 1 year. Longitudinal Targeted Minimum Loss‐based Estimation was used to estimate the primary outcome under sustained use of GLP‐1 RA and DPP 4i, controlling for baseline and time‐varying confounding.
Results
We included 16 619 GLP‐1 RA initiators and 34 196 DPP‐4i initiators, each with 2.8 HbA1c measurements per patient‐year. At 1 year, the probability of any HbA1c improvement was 82.7% (95% CI: 82.0% to 83.4%) under sustained GLP‐1 RA versus 67.1% (95% CI: 66.5% to 67.6%) under DPP‐4i, an absolute difference of 15.7% (95% CI: 14.8% to 16.5%). GLP‐1 RA treatment was also associated with a lower all‐cause mortality risk, with absolute reductions of 0.4% (95% CI: 0.1% to 0.7%) at 1 year and 1.1% (95% CI: 0.3% to 2.0%) at 3 years.
Conclusion
Within the limitations of this nationwide study and the available data, sustained GLP‐1 RA therapy provided superior glycemic control and was associated with a modest mortality benefit compared with DPP‐4i therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Copenhagen University Hospital, Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Endocrinology and Nephrology, North Zealand University Hospital, Hillerød.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- The Prehospital Center, Region Zealand, Næstved, Denmark.
- Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Kathrine Kold Sørensen, Ulrik Pedersen-Bjergaard, Stefanie Lanzinger
Förderung
- European Union
- European Commission
Zitieren
APA
Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Wood-Kurland, H. K., Pedersen-Bjergaard, U., Andersen, M. P., Michelsen, J., Imberg, H., Lind, M., Hallström, S., Lanzinger, S., Munch, A., Ohlendorff, J. S., Gerds, T. A., Torp-Pedersen, C., & REDDIE Consortium (2026). Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes. Diabetes, Obesity and Metabolism, 28(5), 3974-3984. https://doi.org/10.1111/dom.70581
Vancouver
Sørensen KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, Pedersen-Bjergaard U, Andersen MP, et al. Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes. Diabetes, Obesity and Metabolism. 2026;28(5):3974-3984. doi:10.1111/dom.70581
BibTeX
@article{Srensen2026,
author = {Sørensen, Kathrine Kold and Yazdanfard, Puriya Daniel Würtz and Zareini, Bochra and Wood-Kurland, Hannah Karin and Pedersen-Bjergaard, Ulrik and Andersen, Mikkel Porsborg and Michelsen, Jens and Imberg, Henrik and Lind, Marcus and Hallström, Sara and Lanzinger, Stefanie and Munch, Anders and Ohlendorff, Johan Sebastian and Gerds, Thomas Alexander and Torp-Pedersen, Christian and REDDIE Consortium, REDDIE Consortium},
title = {Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {5},
pages = {3974--3984},
doi = {10.1111/dom.70581}
}
EUVIMED